| Trial ID: | L0821 |
| Source ID: | TCTR20170511001
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
Has Results
|
| Results: |
https://doi.org/10.1111/jgh.15580
|
| Conditions: |
Non-alcoholic fatty liver disease
Diabetes patient <br>NAFLD<br>DM type II<br>Insulin resistance<br>SGLT2 inhibitor<br>Fatty liver<br>;NAFLD<br>DM type II<br>Insulin resistance<br>SGLT2 inhibitor<br>Fatty liver<br>
|
| Interventions: |
Dapagliflozin 10 mg Tablets, Oral, Once Daily, 12 weeks,Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 12 weeks;Experimental Drug,Placebo Comparator Drug;Dapagliflozin,Placebo
|
| Outcome Measures: |
To evaluate the effect of Dapagliflozin on improvement of NAFLD 12 weeks Liver attenuation index by Non-contrast CT scanImprovement of NASH and metabolic parameters 12 weeks measured all fat area, visceral fat area, subcutaneous fat area and girth by semiautomatic software ,Improvement of body composition 12 weeks Body weight, Body mass index, waist circumference, visceral fat to subcutaneous fat ratio in non-contrast CT scans,Improvement od metabolic parameter 12 weeks HOMA-IR, Leptin, adiponectin and TNF-alpha
|
| Sponsor/Collaborators: |
The Faculty of Medicine endownment Fund
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Phase 4
|
| Enrollment: |
40
|
| Study Type: |
Interventional
|
| Study Designs: |
Randomized
|
| Start Date: |
11/05/2017
|
| Completion Date: |
29/12/2017
|
| Results First Posted: |
12/06/2021
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Thailand
|
| URL: |
www.thaiclinicaltrials.org/show/TCTR20170511001
|
